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บทคดัยอ่  
วตัถปุระสงค:์ เพื่อทดสอบว่า polyvinyl acetate (PVAc) ทัง้ชนิดน้ําหนักโมเลกุล
ตํ่า (113k) และสงู (500k) ในการเป็น release controlling agent ในระบบ 
implant matrix system ของ 2% 17β-estradiol (E2) วิธีการศึกษา: ใชส้าร 
plasticizer สองชนิดคอื triethyl citrate (TEC) ซึง่เป็นละลายน้ํา และ diethyl 
phthalate (DEP) ซึง่ไมล่ะลายน้ํา เพือ่เปลีย่นค่าความยดืหยุน่ของเมทรกิซ ์ใชส้าร 
polyvinylpyrrolidine เป็น releasing modifier ใชว้ธิ ีsolvent evaporation เพื่อ
เตรยีม solid dispersion ของ E2 ในโพลเิมอร ์แลว้อดัในแม่พมิพใ์หไ้ด ้implant 
matrix ขนาดเสน้ผ่านศูนยก์ลาง 2 มม. และยาว 10 มม. ผลการศึกษา: พบว่า 
PVAc ทัง้ชนิดทีม่น้ํีาหนักโมเลกุลสงูหรอืตํ่า เมื่อไม่ผสม plasticizer ใหอ้ตัราการ
ปลดปล่อย E2 ไม่ต่างกนั ใน phosphate buffer pH 7.4 โดยปลดปล่อย 14% 
ในช่วง 28 วนั สว่น PVAc ทีผ่สม plasticizer ใหอ้ตัราการปลดปล่อย E2 ทีต่่างกนั 
โดยการปลดปล่อย E2 เพิม่ขึน้เมื่อสดัสว่น plasticizer เพิม่ขึน้ และเมื่อเตมิ PVP 
K30 พบว่าอตัราการปลดปล่อยเพิม่ขึน้ ลกัษณะจลนศาสตร์การปลดปล่อย E2 
จาก implant matrix ทีม่ ีPVAc เป็น release controlling agent สามารถอธบิาย
ไดด้ว้ย Higuchi model ซึ่งอธบิายการปลดปล่อยดว้ยกระบวนการแพร่ สรปุ: 
สามารถใช ้PVAc ในระบบนําสง่ยาแบบเน่ินสาํหรบั matrix implant ของยา 17β-
estradiol 
คาํสาํคญั: 17β-estradiol, implant, polyvinylacetate, triethyl citrate, diethyl 
phthalate, polyvinylpyrrolidone  
 
 
Abstract 
Objective: To apply two different, low (113K) and high (500K), molecular 
weights polyvinyl acetate (PVAc) as the release controlling agent in 2% 
17β-estradiol (E2) implant matrix system. Method: Two plasticizers, triethyl 
citrate (TEC, a water-soluble plasticizer or diethyl phthalate (DEP, a water-
insoluble plasticizer) were incorporated to alter the flexibility of the matrix. 
Polyvinylpyrrolidone (PVP K30) was used as the releasing modifier. Solid 
dispersion of E2 in polymer was prepared by solvent evaporation method 
and compressed in a mold to have an implant matrix of 2 mm in diameter 
and 10 mm in length. Results: The unplasticized PVAc of different 
molecular weights did not provide difference in E2 release rate in 
phosphate buffer pH 7.4, about 14% of E2 was gradually released from the 
matrices during 28 days. Implants using plasticized PVAc of different 
molecular weights gave different drug release rates. E2 released from 
implants increased with increasing weight percent of plasticizers and 
adding PVP K30 promoted more drug release. Release kinetic of the PVAc 
implant matrix was best described by Higuchi model which indicated drug 
release by diffusion process. Conclusion: PVAc could be applied in 17β-
estradiol matrix implant for long term drug delivery.  
Keywords: 17β-estradiol, implant, polyvinylacetate, triethyl citrate, diethyl 
phthalate, polyvinylpyrrolidone  
 
Introduction
17β-estradiol (E2) is the most potent natural estrogen 
and mainly prescribed in case of postmenopausal symptoms 
as a part of hormone replacement therapy (HRT), either 
alone or in combination with another female hormone.1 
Furthermore, long-term therapy can prevent cardiovascular 
disease and osteoporosis.2 Estradiol has a good oral 
absorption but poor bioavailability because of first-pass 
metabolism. As a result, oral route administration leads to 
undesirable side effects due to increased levels of active 
metabolites including estrone and estriol in the blood 
circulation.3 Although a transdermal patch of estradiol offers 
a number of advantages over oral route, once detached the 
patient will not receive optimum treatment. Subcutaneous 
implant delivery system may be favorable choice for HRT. 
E2-implant is protected from the first-pass metabolism of 
traditional oral route and thus offers the patient compliance.  
Several contraceptive implants containing different 
progestogens were developed and commercially available. It 
has been reported that the polymers used as carriers in 
controlling drug release from matrix implant such as silicone 
elastomer and ethylene vinyl acetate (EVA) copolymer.4 It 
has been continuously reported for an application of different 
polymer carriers in controlling drug release form matrix 
implant. Several studies attempted to use acrylate polymers, 
i.e. Eudragit RS and Eudragit RL, as a release controlling 
agent in 17β-estradiol and norethindrone implant.5-7  
Vinyl polymer such as polyvinyl acetate (PVAc) has been 
widely used as a release controlling agent in orally controlled 
release system. PVAc is water insoluble polymer which is 
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slightly hydrophilic and able to absorb water to a slight 
extent. PVAc has been reported to be effective in controlling 
the release of various chemical entities, including 
theophylline and chlorpromazine hydrochloride.8-10 But the 
application of this polymer in implant matrix system has not 
been reported. PVAc might be regarded as non-bio-
degradable polymer. As far as literature search has been 
done, there has been no report on an investigation of 
biodegradability of PVAc. PVAc emulsion was developed 
and tested as liquid embolisation materials in rats and in a 
patient, it was observed that PVAc did not induce a 
deleterious reaction in living tissue.11  
Polyvinylpyrrolidone (PVP) is a water soluble polymer 
often used as releasing modifier in matrix system. It has a 
significant effect on the release rate, because it is rapidly 
leached from the system to form the pore structure, which 
then allows the active agent to diffuse out faster than it 
would have done otherwise. Diffusion of the dissolution 
medium into the matrix is also facilitated. The mechanisms 
and the extent by which this polymer might affect drug 
release have been subjects of some studies.12,13 Moreover, 
the release rate can also be modified by varying the 
physicochemical and mechanical properties of the matrix. A 
plasticizer is an additive that is added to polymer making it 
softer, more flexible (by decreasing the glass-rubber 
transition temperature, Tg, of polymer), and easier to 
process. The plasticizers may increase the amount of drug 
release with increasing chain mobility of the polymer by 
altering polymer structure.14  
The aim of the present study was to investigate an 
application of TVAc with two different molecular weights as 
release controlling agent in matrix implant containing 17-
estradiol as an active agent. In addition, drug release from 
PVAc matrices containing various weight percents of 
plasticizer and PVP as release modifier were studied. 
 
Method 
Materials  
17β-estradiol (E2) and benzalkonium chloride (BAC) were 
purchased from Fluka Chemica, Germany. Polyvinyl acetate 
(PVAc) with molecular weight of 500,000 (500K) and 
113,000 (113K) were purchased from Sigma-Aldrich 
Chemical Co., Inc. (USA). Polyvinylpyrrolidone (PVP) K30 
were purchased from Seinghai Chemical Industrial (China). 
Triethyl citrate (TEC) and diethyl phthalate (DEP) were 
purchased from Fluka Chemica, Germany. Acetonitrile was 
of a HPLC grade purchased from Fisher Scientific, UK.  
  
Preparation of E2 in Polymer Solid Dispersions  
Various compositions of drug-polymer solid dispersion as 
presented in Table 1 were prepared. Weighed amounts of 
PVAc, PVP and plasticizer and the drug were dissolved in 
10 mL ethanol. This mixture was poured onto a glass plate 
and the solvent was allowed to evaporate off overnight at 30 
oC. Dried samples were kept in a desiccator over silica gel 
beads for the further experiments.  
 
Preparation of Implants  
The viscous solid dispersion mass prepared according to 
the procedure described above was packed into plastic 
syringe then injected into the mold of rod shape with 2 mm 
in diameter, then compressed to a solid dispersion with the 
punch at a constant pressure of 1500 psi for 60 seconds 
using hydraulic press (Caver®, USA). The mold was kept at 
a temperature of 50 oC for 1 hour. The implant samples 
were kept in a desiccator over silica gel beads for further 
experiments. Weight of an implant was about 25 mg.  
 
Table 1 Formulations of implant containing 2% E2 using 
different MWs of PVAc* with and without different 
percent weights of PVP and plasticizers**.  
Formulation code Plasticizer (%) 
Mixing ratio of 
PVAc:PVP 
E2-implant - 100:0 
E2-10% plasticizer implant: 10 100:0 
-PVP 10% 10 90:10 
-PVP 20% 10 80:20 
-PVP 30% 10 70:30 
E2-15% plasticizer implant: 15 100:0 
-PVP 10% 15 90:10 
-PVP 20% 15 80:20 
-PVP 30% 15 70:30 
E2-20% plasticizer implant: 20 100:0 
-PVP 10% 20 90:10 
-PVP 20% 20 80:20 
-PVP 30% 20 70:30 
 * Two molecular weights were used: 500K or 113K. 
 ** Two plasticizers were used: TEC or DEP.  
 
Thermal Analysis 
Thermal analysis was carried out using differential 
scanning calorimetry apparatus with a refrigerated cooling 
system (Model 822e, Mettler Toledo, Schwerzenbach, 
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Switzerland) to determine Tg of polymer and solid 
dispersions. The calorimeter was calibrated using indium. 
Approximate sample of 3 - 5 mg was added to standard 
aluminium pan with cover and scanned using heating 0 °C to 
200 °C at 5 °C/min; cooling down to 0 °C at 20 °C/min; 
heating up to 200 °C at a rate of 5 °C/min.   
 
Content of E2 and DEP in Implant Matrix 
The content of E2 and DEP in the matrix was 
quantitatively determined by validated reversed phase HPLC 
method (Shimadzu Class VP, Japan) modified from the 
report by Ye and Chien (1996).15 A Synergi Fusion-RP ODS 
column (5 μm; 250 x 4.6 mm in diameter, Inersil® ) was used 
as an analytical column. Prednisolone was used as an 
internal standard. The solution for E2 content analysis was 
prepared by dissolving the matrix implant with 10 ml 
methanol, and 50 μl of internal standard solution was added. 
The solution was adjusted to volume with mobile phase. 
Samples of 50 μl were injected and a water:acetonitrile 
combination of 50:50 (v:v) was used as the mobile phase at 
a flow rate of 1.0 ml/min. The UV detector was operated at 
280 nm. Under these conditions, the E2 and DEP peaks 
appeared at retention times of 7.9 and 9.9 min., respectively.  
 
Drug release study 
Release studies of E2 implants were conducted in 
phosphate buffer (PB) pH 7.4 with 3.5% w/v benzalkonium 
chloride under sink conditions. The E2 implants were 
individually placed in a screw-capped test tube containing 
3.0 ml of release medium. The sample test tubes were 
constantly shaken at 120 rpm in a shaking incubator at 37 °C. 
Release medium was taken out periodically and replaced by 
fresh release medium. The samples were filtered through 
0.45 μm membrane filter and analyzed for E2 using HPLC 
method as described above. 
 
Results and Discussion 
 
An E2 implant produced by compressing a solid 
dispersion prepared by solvent evaporation in a mold is 
shown in Figure 1(a). E2 implant was in rod shape and 
translucent matrix with diameter of 2 mm and length of 10 
mm. Furthermore, the E2 implant after in vitro release study 
became opaque as shown in Figure 1(b).  
 
 
(a) 
  
 
(b) 
Figure 1 Photographs of E2-implant using PVAc as a release 
controlling agent (a) before in vitro release study (b) 
after in vitro release study.  
 
DSC with heating program as described was applied to 
determine the glass-rubber transition temperature (Tg) of E2 
implants prepared using low and high molecular weight 
PVAC with and without a plasticizer and PVP are presented 
in Tables 2 and 3. It was observed that the Tg values of 
pure low and high MW PVAc were apparently not different, 
45.23 and 45.72 °C, respectively. The Tg of E2 implant 
prepared using low and high molecular weight of PVAc were 
determined to be 46.26 °C and 46.93 °C, respectively, which 
slightly increased comparing with pure polymer without drug. 
When 10%, 15%, and 20% of TEC or DEP was incorporated 
to high MW PVAc implant, the Tg values were determined in 
the following order: 29.80, 24.64 and 18.48 °C for TEC and 
32.97, 26.72 and 21.64 °C for DEP, respectively. For low 
MW PVAc implant, the Tg values were determined in the 
following order: 29.56, 23.81 and 18.98 °C for TEC and 
30.64, 25.89 and 20.89 °C for DEP. The addition of 
plasticizer from 10% to 20% caused a pronounced decrease 
in Tg values. These effects on significant Tg decrease could 
be related to a flexibility of the structure of polymer 
molecules and the compatibility of the plasticizers with the 
polymers. Both TEC and DEP apparently exhibited the same 
degree of Tg value reduction. This indicates that both TEC 
and DEP would be also the efficient plasticizer for thermal 
processing of PVAc, ie. hot melt extrusion process, to 
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prepare controlled release products. It was observed that 
adding PVP into the implant formulations slightly changed Tg 
values at all levels of plasticizer. It seemed that when 
varying PVP amounts from 10 to 30% did not much alter Tg 
values of the implants.   
 
Table 2 Tg of E2-implant using low molecular weight PVAc 
(113K) when incorporated with different amounts of 
PVP and plasticizers.  
Formulation 
code 
Tg  
(oC) 
Formulation 
code 
Tg  
(oC) 
Formulation 
code 
Tg  
(oC) 
Pure E2 84.64 Pure PVAc 45.23 E2-implant 46.26 
E2-10%T implant: 29.56 E2-20% T implant: 18.98 E2-15% D implant: 25.89 
 PVP 10% 28.31  PVP 10% 16.73  PVP 10% 25.31 
 PVP 20% 28.23  PVP 20% 18.81  PVP 20% 23.97 
 PVP 30% 26.97  PVP 30% 18.48  PVP 30% 23.39 
E2-15%T implant: 23.81 E2-10% D implant: 30.64 E2-20% D implant: 20.89 
 PVP 10% 22.81  PVP 10% 30.81  PVP 10% 19.31 
 PVP 20% 22.72  PVP 20% 30.22  PVP 20% 19.23 
 PVP 30% 21.39  PVP 30% 30.90  PVP 30% 17.22 
* T = TEC, D = DEP  
 
Table 3 Tg of E2-implant using high molecular weight PVAc 
(500K) when incorporated with different amounts of 
PVP and plasticizers.  
Formulation 
code 
Tg  
(oC) 
Formulation 
code 
Tg  
(oC) 
Formulation 
code 
Tg  
(oC) 
Pure PVAc 45.72 E2-implant 46.93   
E2-10% T implant: 29.80 E2-20%T implant: 18.48 E2-15%D implant: 26.72 
 -PVP 10% 31.40  -PVP 10% 19.06  -PVP 10% 27.49 
 -PVP 20% 29.23  -PVP 20% 16.56  -PVP 20% 27.40 
 -PVP 30% 29.69  -PVP 30% 17.81  -PVP 30% 25.48 
E2-15% T implant: 24.64 E2-10% D implant: 32.97 E2-20%D implant: 21.64 
 -PVP 10% 23.64  -PVP 10% 32.90  -PVP 10% 22.48 
 -PVP 20% 22.56  -PVP 20% 33.07  -PVP 20% 15.57 
 -PVP 30% 21.90  -PVP 30% 31.98  -PVP 30% 20.32 
* T = TEC, D = DEP  
 
In all cases, E2 content in matrix implants was found to 
be well within 97 - 103%. Moreover, the standard deviation 
of each formulation was very low, confirming homogeneous 
dispersion of the drug in the matrices. The E2 release of all 
formulations was studied in phosphate buffer pH 7.4 with 3.5% 
w/v BAC. The E2 release from the matrices using two 
polymer carriers of high and low MW PVAc are presented in 
Figure 2. The PVAc of different molecular weights did not 
provide difference in E2 release rate. About 14% of E2 was 
gradually released from the matrices during 28 days. The 
porosity and tortuosity of polymeric network seemed not to 
be the important factors in controlling E2 release from this 
system. From the previous study by Wiranidchapong (2006), 
it was indicated that poor solubility of E2 in the release 
medium would predominate in controlling the release rate of 
E2 from implant matrix using acrylate polymer (solubility in 
3.5 % w/v BAC in PB 7.4 at 37 °C was 891.29 μg/ml)7. So 
the difference of the MW of PVAc used as the carrier might 
not significantly change E2 release profiles.  
 
Figure 2 The release of E2 from matrix implants using different 
low (113K) and high (500K) molecular weight PVAc. 
 
The dissolution profiles of E2 from matrices of low and 
high MW PVAc with 0, 10, 15 and 20 % TEC or DEP are 
shown in Figure 3 and 4. Increasing the plasticizer amount 
resulted in an increase in drug release for all formulations 
when compared with the matrices without plasticizer. The 
obtained results indicated that the E2 release from PVAc of 
various weight percents of plasticizer increased in the 
following order: 20%, >15%, >10%, and >0%. Comparing 
with implants without plasticizer, adding plasticizers from 10 
to 30% caused an increase of drug release between 2-8 % 
for low MW PVAc implants but drug release increasing were 
higher between 8-13 % for high MW PVAc implants.  
  
 
 
(a) 
  
 
(b) 
Figure 3 The release of E2 from matrices using low molecular 
weight PVAc with 0%, 10%, 15% and 20 % of TEC 
(a) and DEP (b) at various time intervals for 28 days.  
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(a) 
  
 
(b) 
 
Figure 4 The release of E2 from matrices using high molecular 
weight PVAc with 0%, 10%, 15% and 20% of TEC (a) 
and DEP (b) at various time intervals for 28 days.  
 
Drug release from each implant was fitted to three 
different release models: the zero order, the first order, and 
the Higuchi model. The zero order model can be expressed 
as the following equation:  
Qt = Q0 + k0t,  
 
where Qt is the amount of drug released in time t, Q0 is the 
initial amount of drug in release medium, and k0 is the zero-
order release constant. The first-order model can be 
expressed according to the equation: 
Qt = Q0e-k1t,  
 
where Qt is the amount of drug remaining in the matrix at 
time t, Q0 is the initial amount of drug in the matrix, and k1 is 
the first order release constant. The Higuchi model equation 
is expressed below: 
 Qt = kH t1/2,  
where Qt is the amount of drug released in time t, kH is the 
Higuchi release constant. 
 
The coefficient of determination (R2) obtained from each 
fit was used as a criterion to choose the best model for drug 
release. It was found that Higuchi model was best described 
for drug release characteristic. The Higuchi release rate (% 
hr-1/2) were calculated and plotted against the percentage of 
plasticizers as presented in Figure 5. The effect of 10%, 15% 
and 20% of TEC on drug release was different from 10%, 15% 
and 20% of DEP. In case of the implants using low MW 
PVAc, the Higuchi constant of 10% of DEP (2.938% hr-1/2) 
was slightly faster than that of 10% TEC (2.860% hr-1/2). The 
Higuchi release rate of the matrices with 15% and 20% of 
DEP (3.527% hr-1/2 and 4.032% hr-1/2, respectively) was also 
clearly faster than those with 15% and 20% of TEC (2.914% 
hr-1/2 and 3.656% hr-1/2, respectively). In case of the matrices 
using high MW PVAc, the Higuchi release rate of matrices 
with all levels of TEC (4.169% hr-1/2, 4.953% hr-1/2 and 5.049% 
hr-1/2) was faster than those with DEP (3.695% hr-1/2, 3.950% 
hr-1/2 and 4.498% hr-1/2). Adding plasticizer in matrices 
increased drug release when compared with the release rate 
of unplasticized implants using low MW PVAc (2.723 % hr-1/2) 
and high MW PVAc 2.604 % hr-1/2). It was seen that an 
increase of plasticizer amount in matrices caused an 
increase in release rate. The effect of TEC on drug release 
was different from the system containing DEP depending on 
the MW of PVAc. These results indicated the influence of 
different types and various weight percents of plasticizer to 
drug release rates. As it has been shown that both TEC and 
DEP are good plasticizers for PVAc by effectively reducing 
the Tg of implants. Therefore, both plasticizers increased 
chain mobility of polymer resulting in an increase of drug 
release.16 However, an increase of plasticizer causing a 
decrease of polymer composition in the formulation might 
also have an increasing influence on the drug release rate in 
particular at 20% level of plasticizer.  
  
 
Figure 5 The Higuchi release rate (% hr-1/2) of the matrix 
implants using low and high molecular weight PVAc 
containing various percentages of TEC or DEP.  
 
Surprisingly, plasticized PVAc implants showed the effect 
of MW on drug release when compared with the implants 
using the polymer without plasticizer. As it was seen implant 
using PVAc of low MW exhibited slower drug release rate 
than of high MW at the same level and type of plasticizer. 
This effect could be the different leaching of plasticizer from 
the implant matrices. Bodmeier and Paeratakul (1992) 
ไทยเภสชัศาสตรแ์ละวทิยาการสขุภาพ ปี 6 ฉบับ 3, กค. – กย. 2554 219  Thai Pharm Health Sci J Vol. 6 No. 3, Jul. – Sep. 2011 
indicated leaching of plasticizer from acrylic or ethylcellulose 
film depending on type, concentration, water solubility and 
affinity for polymer of plasticizer as well as other ingredients 
that adding in polymeric film.17 Leaching of plasticizer in 
dissolution medium could alter it mechanical property and 
permeability of polymer. To demonstrate this effect, the DEP 
content remaining in the matrix after immersion in dissolution 
medium for 28 days was, therefore, determined as presented 
in Table 4. The low MW PVAc implant containing DEP 
exhibited a loss of plasticizer approximately up to 35 - 39 % 
when compared with that of high MW of PVAc implants 
showed about 25 - 26% loss. Leaching of plasticizer from 
the matrix might compete with E2 release from the implant 
system. Therefore higher leaching of plasticizer from low 
MW PVAc implant resulted in slower drug release rate than 
that of high MW PVAc implant.  
 
Table 4 Amount of DEP content remaining in low and high MW 
PVAc before and after immersion in dissolution 
medium for 28 days.  
 Diethyl Phthalate (DEP)(%) 
Low MW PVAc High MW PVAc 
10 15 20 10 15 20 
Before immersion 98.87 92.72 91.47 89.91 92.22 90.21 
After immersion  58.94 57.08 54.94 64.48 67.20 63.51 
Plasticizer loss 39.63 35.64 36.53 25.43 25.02 26.70 
 
The cumulative releases of E2 from matrix composed of 
PVP 10, 20, and 30% with 10, 15, and 20 % TEC or DEP 
are shown in Figure 6-9. PVP was added as a water-soluble 
polymer additive to modify the release profile of E2 from the 
matrix implants. During dissolution process, the PVP leached 
and created more porous matrix through which the drug 
diffused13. It was seen that PVP exhibited an increasing 
effect on drug release when adding in plasticized PVAc 
implants. When increased the amount of PVP levels 
between 10-30% in PVAc matrices with all TEC or DEP 
levels from 10, 15 and 20%, the E2 release from low MW 
PVAc implants at day 28th increased from 24.61-26.26% to 
31.44-33.13% and 41.43-42.60%, respectively, for TEC and 
22.17-22.62% to 24.68-30.88% and 34.84-38.28%, 
respectively, for DEP; but in case of high MW PVAc implants 
the E2 release at day 28th increased from 31.64-36.50%, 
36.24-41.18% to 44.80-4.57%, respectively, for TEC and 
35.96-37.37%, 41.22-42.36% to 45.43-48.13%, respectively, 
for DEP.   
 
(a) 
 
(b) 
  
(c) 
Figure 6 The release of E2 from low MW PVAc matrices 
containing 10% (a), 20% (b) and 30% (c) PVP, with 
10%, 15% and 20% of TEC at various time 
intervals for 28 days.  
 
 
(a) 
 
(b) 
 
(c) 
Figure 7 The release of E2 from low MW PVAc matrices 
containing 10% (a), 20% (b) and 30% (c) PVP, with 
10%, 15% and 20% of DEP at various time 
intervals for 28 days.  
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(a) 
 
(b) 
 
(c) 
Figure 8 The release of E2 from high molecular weight PVAc 
matrices containing 10% (a), 20% (b) and 30% (c) 
PVP, with 10%, 15% and 20 % of TEC at various 
time intervals for 28 days.  
 
 
(a) 
 
(b) 
 
(c) 
Figure 9 The release of E2 from high molecular weight PVAc 
matrices containing 10% (a), 20% (b), 30% (c) PVP, 
with 10%, 15% and 20% of DEP at various time 
intervals for 28 days.  
It was found that all profiles were best fitted to Higuchi 
release model. The plots of the Higuchi release rate of all 
formulations in relationship with percentage of added PVP at 
various TEC or DEP levels were presented in Figure 10. It 
was likely that the change of PVP quantity from 10 to 30 % 
did not exert much more effect on drug release from the 
matrices. It was observed that addition of plasticizers gave 
more effect on drug release of the matrices. 
 
Figure 10 Effect of % PVP in the implant matrices on the 
Higuchi release rate (% hr-1/2) of E2 from low (113K) 
and high (500K) MW PVAc implants containing 
different % TEC and DEP.  
 
Conclusion 
PVAc could be used as a release controlling agent in an 
implantable controlled release drug delivery system of E2. 
The E2 implants using PVAc alone released approximately 
14 % of E2 within 28 days. Incorporation of plasticizers and 
water soluble polymers could modify E2 release rate. 
Leaching of plasticizer from the PVAc matrices should take 
into account that may affect on theirs drug release behaviors. 
The information obtained from this study would be useful in 
future work when apply the hot melt extrustion (HME) 
technique to prepare a solid dispersion implant device using 
PVAc as the polymeric base.  
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